| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| SNY | Sanofi | $43.75 | $109.14B | Downtrend |
Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
http://www.zacks.com/stock/news/373225/regeneron-alnylam-extend-collaboration-for-rnai-therapeutics?cid=CS-ZC-FT-373225
Apr 09, 2019 - Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).
0
AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes
http://www.zacks.com/stock/news/366338/astrazenecas-forxiga-gets-nod-in-japan-for-type-i-diabetes?cid=CS-ZC-FT-366338
Mar 28, 2019 - AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.
0
Lilly (LLY) Signs New Immunology Deal With Private Biotech
http://www.zacks.com/stock/news/365638/lilly-lly-signs-new-immunology-deal-with-private-biotech?cid=CS-ZC-FT-365638
Mar 27, 2019 - Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
0
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
http://www.zacks.com/stock/news/364371/ascendis-pivotal-growth-hormone-deficiency-study-data-positive?cid=CS-ZC-FT-364371
Mar 25, 2019 - Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
0
Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug
http://www.zacks.com/stock/news/364211/lexicon-falls-as-fda-denies-approval-to-type-i-diabetes-drug?cid=CS-ZC-FT-364211
Mar 25, 2019 - FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.
0
AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes
http://www.zacks.com/stock/news/364120/astrazenecas-forxiga-gets-ec-approval-for-type-i-diabetes?cid=CS-ZC-FT-364120
Mar 25, 2019 - AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.
0
What's Next for Lexicon Pharmaceuticals?
https://www.fool.com/investing/2019/03/25/whats-next-for-lexicon-pharmaceuticals-after-fda-r.aspx?source=iedfolrf0000001
Mar 25, 2019 - American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.
0
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
http://www.zacks.com/stock/news/362304/emergent-begins-phase-iii-study-on-anthrax-vaccine-av7909?cid=CS-ZC-FT-362304
Mar 20, 2019 - Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
0
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
http://www.zacks.com/stock/news/360917/regeneron-sanofi-get-ec-nod-for-label-expansion-of-praluent?cid=CS-ZC-FT-360917
Mar 18, 2019 - Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
0
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
http://www.zacks.com/stock/news/359263/biotech-stock-roundup-regn-gets-fda-nod-for-dupixent-other-pipeline-news?cid=CS-ZC-FT-359263
Mar 13, 2019 - Key highlights of the past week are regulatory and pipeline developments.
0
Page 1>